Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 210 clinical trials
Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma

bendamustine, as well as the established clinical efficacy of bendamustine and isatuximab as single agents for multiple myeloma, the logical next step is to combine isatuximab with bendamustine and prednisone

lymphoma
neutrophil count
monoclonal antibodies
measurable disease
monoclonal protein
  • 0 views
  • 21 Apr, 2022
  • 1 location
ASCT With Nivolumab in Patients With Multiple Myeloma

This is an open-label, single center trial of Autologous Stem Cell Transplantation (ASCT) with nivolumab in multiple myeloma patients to determine the efficacy and safety of ASCT and PD1

colony stimulating factor
melphalan
induction therapy
cell transplantation
measurable disease
  • 3 views
  • 25 Apr, 2022
  • 1 location
Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma

This trial studies how well cryocompression therapy works in reducing bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Peripheral neuropathy (nerve pain or tingling in

chemotherapy regimen
bortezomib
cancer
multiple myeloma
peripheral neuropathy
  • 2 views
  • 21 Apr, 2022
  • 1 location
Short Course Daratumumab in Patients With Multiple Myeloma

lenalidomide has on people and their risk of multiple myeloma. The study is also designed to test the amount of remaining myeloma cells in your body after treatment with daratumumab which is known as minimal

neutrophil count
maintenance therapy
platelet count
bisphosphonate
progressive disease
  • 10 views
  • 13 May, 2022
  • 7 locations
68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma

Chemokine receptor-4 (CXCR4) is overexpressed in multiple myeloma (MM) cells. 68Ga-pentixafor is a radio-labled tracer for CXCR4 . 68Ga-pentixafor PET/CT has shown good diagnostic performance in

  • 0 views
  • 13 May, 2022
  • 1 location
Iberdomide Maintenance Therapy in Patients With Multiple Myeloma

This is a phase II study to determine the feasibility, safety and efficacy of iberdomide maintenance therapy post-ASCT. Iberdomide will be dosed at 1.0 mg PO daily for days 1-21 of a 28-day cycle. Treatment will continue until disease progression or toxicity. A maximum of 38 subjects will be enrolled. …

  • 0 views
  • 11 May, 2022
  • 1 location
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

This is a registration, open-label phase 1 study of the combination of ibrutinib/lenalidomide:/dexamethasone in women and men with relapsed/refractory multiple myeloma.

neutrophil count
platelet count
kappa light chain
g-csf
filgrastim
  • 2 views
  • 13 Apr, 2022
  • 5 locations
Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (CarMob)

This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and G-CSF

neutrophil count
kappa light chain
platelet count
filgrastim
carfilzomib
  • 6 views
  • 22 Apr, 2022
  • 1 location
A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma

This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of TNB-383B, a BCMA x CD3 T-cell engaging bispecific antibody, in participants with relapsed or refractory MM who have received at least 3 prior lines of therapy. The study consists of 2 portions, a monotherapy …

neutrophil count
bcma
bone marrow transplant
serum calcium
measurable disease
  • 12 views
  • 22 Apr, 2022
  • 1 location
BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

)-specific chimeric antigen receptor (CAR) and manufactured with a new process. CAR-T cells will be investigated as a single agent in relapsed/refractory multiple myeloma

bcma
measurable disease
immunomodulatory imide drug
carfilzomib
refractory multiple myeloma
  • 0 views
  • 23 Apr, 2022
  • 3 locations